Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
Macrophage Contributions Towards the Sarcoma Immune Architecture and Response to Stimulator of Interferon Genes Agonist Therapies
EF 2020-21
Résumé
Undifferentiated pleomorphic sarcoma (UPS) is an aggressive, highly metastatic malignant tumour of muscle. UPS is resistant to all available systemic therapies and metastatic disease is rapidly fatal. New UPS therapies are desperately needed. The STING (STimulator of INterferon Genes) immune pathway is a promising new therapeutic target for cancer immunotherapy. Using a small molecule STING agonist (SMSA), we have recently demonstrated very promising anti-sarcoma effects and durable survival following intra-tumoural STING activation in a mouse model of UPS. To pursue clinical application of SMSA therapy, it is important to further understand how STING activation works in sarcoma. The precise intra-tumoural cell populations activated by SMSAs are poorly characterized. Macrophages are the most abundant immune cell in UPS tumours and are sensitive to SMSAs. We therefore hypothesize that intra-tumoural macrophages are essential for the initiation of anti-sarcoma immune responses following SMSA therapy. To test this hypothesis, we have developed the following aims: (Aim1) To evaluate the therapeutic effects of STING activation in the context of macrophage deficiency; (Aim 2) To determine if STING pathway activation restricted to intra-tumoural macrophages can recapitulate the therapeutic effects of SMSAs. Liposomal clodronate will be used to deplete intra-tumoural macrophages before SMSA therapy. A novel transgenic mouse line engineered to express inducible, activated STING exclusively in macrophages will also be evaluated. This study will provide insight into the role of UPS tumour macrophages in the therapeutic mechanisms of STING activation in UPS tumours. This study will also generate new knowledge of how the UPS tumour immune microenvironment is shaped by macrophages.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449492
Name
Hildebrand Kurt N
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Macrophage Contributions Towards the Sarcoma Immune Architecture and Response to Stimulator of Interferon Genes Agonist Therapies
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Immunotherapy; Macrophage Depletion; Macrophages; Mouse; Sarcoma; Soft Tissue Sarcoma; Solid Tumour; Sting Cancer Therapy
Abstract
Undifferentiated pleomorphic sarcoma (UPS) is an aggressive, highly metastatic malignant tumour of muscle. UPS is resistant to all available systemic therapies and metastatic disease is rapidly fatal. New UPS therapies are desperately needed. The STING (STimulator of INterferon Genes) immune pathway is a promising new therapeutic target for cancer immunotherapy. Using a small molecule STING agonist (SMSA), we have recently demonstrated very promising anti-sarcoma effects and durable survival following intra-tumoural STING activation in a mouse model of UPS. To pursue clinical application of SMSA therapy, it is important to further understand how STING activation works in sarcoma. The precise intra-tumoural cell populations activated by SMSAs are poorly characterized. Macrophages are the most abundant immune cell in UPS tumours and are sensitive to SMSAs. We therefore hypothesize that intra-tumoural macrophages are essential for the initiation of anti-sarcoma immune responses following SMSA therapy. To test this hypothesis, we have developed the following aims: (Aim1) To evaluate the therapeutic effects of STING activation in the context of macrophage deficiency; (Aim 2) To determine if STING pathway activation restricted to intra-tumoural macrophages can recapitulate the therapeutic effects of SMSAs. Liposomal clodronate will be used to deplete intra-tumoural macrophages before SMSA therapy. A novel transgenic mouse line engineered to express inducible, activated STING exclusively in macrophages will also be evaluated. This study will provide insight into the role of UPS tumour macrophages in the therapeutic mechanisms of STING activation in UPS tumours. This study will also generate new knowledge of how the UPS tumour immune microenvironment is shaped by macrophages.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hildebrand, Kurt N
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~